Provided by Tiger Trade Technology Pte. Ltd.

Nurix Therapeutics

19.30
+0.44002.33%
Post-market: 19.18-0.1173-0.61%19:29 EDT
Volume:2.13M
Turnover:41.57M
Market Cap:2.00B
PE:-6.10
High:19.99
Open:18.99
Low:18.92
Close:18.86
52wk High:22.50
52wk Low:8.20
Shares:103.41M
Float Shares:86.36M
Volume Ratio:0.78
T/O Rate:2.47%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.1650
EPS(LYR):-3.0514
ROE:-61.40%
ROA:-31.50%
PB:4.15
PE(LYR):-6.32

Loading ...

Nurix Therapeutics Is Maintained at Outperform by Baird

Dow Jones
·
Jun 18

U.S. RESEARCH ROUNDUP- Datadog, Jabil, Prologis

Reuters
·
Jun 18

Stifel Nicolaus Sticks to Its Buy Rating for Nurix Therapeutics (NRIX)

TIPRANKS
·
Jun 15

Jefferies Sticks to Their Buy Rating for Nurix Therapeutics (NRIX)

TIPRANKS
·
Jun 15

Nurix Therapeutics Price Target Maintained With a $34.00/Share by Needham

Dow Jones
·
Jun 15

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Jun 12

Nurix reports 22.1-month median PFS in Phase 1a trial of BTK degrader bexobrutideg for relapsed/refractory CLL/SLL

Reuters
·
Jun 11

Nurix Therapeutics - Reports 92.9% Objective Response Rate in Second Line Btki-Exposed, Bcl2i-NaÏVe Cll Patients

THOMSON REUTERS
·
Jun 11

Nurix Therapeutics - Responses Observed in High-Risk, Btk Resistant, and CNS-Involved Cll Subgroups

THOMSON REUTERS
·
Jun 11

Nurix Therapeutics - Phase 1a Data Shows 22.1 Month Median Pfs, 83% Orr in Heavily Pretreated Relapsed/Refractory Cll/Sll

THOMSON REUTERS
·
Jun 11

Nurix Therapeutics - Bexobrutideg Well Tolerated With Consistent Safety Profile

THOMSON REUTERS
·
Jun 11

Nurix Therapeutics to Report Updated Phase 1a/B Results for Btk Degrader Bexobrutideg, Highlighting Durable Responses in Relapsed/Refractory Cll/Sll and Promising Activity in Earlier Lines of Therapy

THOMSON REUTERS
·
Jun 11

Nurix Therapeutics Price Target Maintained With a $32.00/Share by HC Wainwright & Co.

Dow Jones
·
Jun 10

Analysts Offer Insights on Healthcare Companies: Edwards Lifesciences (EW), Nurix Therapeutics (NRIX) and Gilead Sciences (GILD)

TIPRANKS
·
Jun 09

Analysts Have Conflicting Sentiments on These Healthcare Companies: Nurix Therapeutics (NRIX) and Incyte (INCY)

TIPRANKS
·
Jun 09

Nurix Therapeutics price target raised to $45 from $41 at Jefferies

TIPRANKS
·
Jun 09

Nurix Therapeutics Is Maintained at Buy by Needham

Dow Jones
·
Jun 08

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Jun 08

Nurix Therapeutics Inc : Needham Raises Target Price to $34 From $26

THOMSON REUTERS
·
Jun 08

Nurix Therapeutics downgraded to Equal Weight at Wells Fargo after Roche deal

TIPRANKS
·
Jun 08